Identification of Potential microRNA Panels for Male Non-Small Cell Lung Cancer Identification Using Microarray Datasets and Bioinformatics Methods.
NSCLC
microRNA
microarray
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
13 Dec 2022
13 Dec 2022
Historique:
received:
23
10
2022
revised:
05
12
2022
accepted:
07
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Background: Non-small cell lung cancer (NSCLC) is still one of the types of cancer with the highest death rates. MicroRNAs (miRNAs) play essential roles in NSCLC development. This study evaluates miRNA expression patterns and specific mechanisms in male patients with NSCLC. Methods: We report an integrated microarray analysis of miRNAs for eight matched samples of males with NSCLC compared to the study of public datasets of males with NSCLC from TCGA, followed by qRT-PCR validation. Results: For the TCGA dataset, we identified 385 overexpressed and 75 underexpressed miRNAs. Our cohort identified 54 overexpressed and 77 underexpressed miRNAs, considering a fold-change (FC) of ±1.5 and p < 0.05 as the cutoff value. The common miRNA signature consisted of eight overexpressed and nine underexpressed miRNAs. Validation was performed using qRT-PCR on the tissue samples for miR-183-3p and miR-34c-5p and on plasma samples for miR-34c-5p. We also created mRNA-miRNA regulatory networks to identify critical molecules, revealing NSCLC signaling pathways related to underexpressed and overexpressed transcripts. The genes targeted by these transcripts were correlated with overall survival. Conclusions: miRNAs and some of their target genes could play essential roles in investigating the mechanisms involved in NSCLC evolution and provide opportunities to identify potential therapeutic targets.
Identifiants
pubmed: 36556276
pii: jpm12122056
doi: 10.3390/jpm12122056
pmc: PMC9780989
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Iuliu Hațieganu University of Medicine and Pharmacy
ID : 1680/46/10.01.2018, 1530/29/18.01.2019, 2463/6/17.01.2020, 1170/4/14.01.2021
Organisme : POC Grant, Competitively Operational Program, 2014-2020
ID : no. 35/01.09.2016, MySMIS 103375
Organisme : PDI-PFE-CDI 2021
ID : no. 40PFE/20.12.2021
Références
Front Cell Dev Biol. 2021 Apr 07;9:643942
pubmed: 33898432
Clin Cancer Res. 2007 May 1;13(9):2795-803
pubmed: 17473213
Curr Genomics. 2018 May;19(4):258-278
pubmed: 29755289
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W498-504
pubmed: 22649059
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ther Adv Med Oncol. 2012 Mar;4(2):51-60
pubmed: 22423264
Oncogene. 2010 Apr 15;29(15):2161-4
pubmed: 20190803
J Thorac Dis. 2017 Oct;9(10):3735-3746
pubmed: 29268381
Int J Mol Sci. 2017 Jul 13;18(7):
pubmed: 28703782
Int J Mol Sci. 2022 May 11;23(10):
pubmed: 35628157
Onco Targets Ther. 2019 Jul 16;12:5729-5739
pubmed: 31410019
Sci Rep. 2017 Mar 30;7:45477
pubmed: 28358118
Front Oncol. 2017 Aug 28;7:193
pubmed: 28894699
Sci Rep. 2016 Apr 21;6:24747
pubmed: 27098600
J Exp Clin Cancer Res. 2019 Oct 29;38(1):433
pubmed: 31665050
Int J Mol Sci. 2019 Feb 16;20(4):
pubmed: 30781524
PLoS One. 2013 Jun 21;8(6):e67581
pubmed: 23805317
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12085-90
pubmed: 19597153
Mol Biol Cell. 2001 Jan;12(1):27-36
pubmed: 11160820
Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4
pubmed: 11459659
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
Drugs. 2012 Jun 19;72 Suppl 1:37-52
pubmed: 22712796
J Neuroimmunol. 2012 Jul 15;248(1-2):32-9
pubmed: 22078708
Exp Cell Res. 2019 Jan 15;374(2):315-322
pubmed: 30528264
Brief Bioinform. 2018 Mar 1;19(2):188-198
pubmed: 28028006
Trends Cancer. 2020 Sep;6(9):775-780
pubmed: 32312682
Noncoding RNA Investig. 2018 Nov;2:
pubmed: 30957073
Biomed Pharmacother. 2019 Mar;111:1103-1111
pubmed: 30841423
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Genes (Basel). 2021 Apr 14;12(4):
pubmed: 33919884
Int J Mol Sci. 2021 Jan 13;22(2):
pubmed: 33451052
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31959728
Cancers (Basel). 2021 Jan 05;13(1):
pubmed: 33526761
BMC Bioinformatics. 2019 Nov 22;20(Suppl 9):344
pubmed: 31757209
ESMO Open. 2018 Apr 13;3(3):e000344
pubmed: 29682332
Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9
pubmed: 26627242
Tumour Biol. 2015 Mar;36(3):1603-12
pubmed: 25384507
PLoS One. 2015 Feb 06;10(2):e0116977
pubmed: 25658832
Curr Opin Oncol. 2004 Mar;16(2):130-5
pubmed: 15075904
Cell Cycle. 2015;14(13):2171-80
pubmed: 25714397
Genomics Proteomics Bioinformatics. 2018 Jun;16(3):200-211
pubmed: 30005964
Pharmacol Res Perspect. 2019 Dec;7(6):e00528
pubmed: 31859460
Exp Mol Med. 2019 Jan 17;51(1):1-10
pubmed: 30700696
Thorac Cancer. 2014 Jan;5(1):31-7
pubmed: 26766969
Future Oncol. 2010 May;6(5):741-67
pubmed: 20465389
Cell Mol Biol Lett. 2019 Nov 20;24:60
pubmed: 31832068
PLoS One. 2015 Jul 15;10(7):e0132767
pubmed: 26177460
Tumour Biol. 2016 May;37(5):5705-14
pubmed: 26831657
Biol Sex Differ. 2018 May 8;9(1):18
pubmed: 29739446
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4347-4357
pubmed: 32041891
Clin Cancer Res. 2015 Oct 1;21(19):4270-7
pubmed: 26429980
Cancers (Basel). 2019 Apr 30;11(5):
pubmed: 31052265
Cancers (Basel). 2020 Mar 31;12(4):
pubmed: 32244548
Oncotarget. 2016 Aug 23;7(34):54965-54972
pubmed: 27463019
Sci Rep. 2017 Jan 03;7:39812
pubmed: 28045090
J Biol Chem. 2020 Dec 11;295(50):17169-17186
pubmed: 33028635